Multiple Sclerosis: KOL Insight 2016

Gain new KOL insights on the latest events happening in multiple sclerosis (MS). Topics covered include; reactions to the latest safety and efficacy data for ibudilast (MediciNova) in progressive MS; the development of RedHill’s RHB 104, a combination antibiotic therapy which includes clarithromycin, clofazimine and rifabutin; the removal of the pregnancy contraindication from the European label of Copaxone (glatiramer acetate; Teva) injection 20mg/ml; as well as opinions on the development and potential future use of generic glatiramer acetate.

*Latest* Update 1: February 2017
Original Publication: Nov 2016
*Purchase of this report includes all updates*

• What do KOLs think of ibudilast’s safety and efficacy?
• If approved, where would ibudilast be positioned in the treatment paradigm?
• How is RHB 104, an oral antibiotic combination, viewed by KOLs?
• How have KOLs reacted to the removal of the pregnancy contraindication from the European label for Copaxone injection 20mg/ml?
• What is the general consensus among KOLs regarding generic versions of Copaxone?

Big changes ahead as Ocrevus nears approval. How will it affect your brand?

Oral therapies are replacing interferons as the mainstay Multiple Sclerosis (MS) treatment, but the big news is the pending approval of Roche/Biogen’s Ocrevus, a powerful monoclonal antibody for relapsing and progressive MS patients that promises to upend the treatment algorithm.

Get the details in KOL Insight: Multiple Sclerosis.

Based on interviews with 12 US and European KOLs, the report gives you their candid thoughts about 12 marketed therapies and 11 more in the pipeline.

You’ll learn what the future holds for interferons, how oral agents are faring, and how pipeline treatments—from sphingosine modulators, to monoclonal antibodies, pharmaceutical-grade biotin, and other novel mechanisms of action—are likely to compete with established therapies.

Request sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

See the Top Takeaways >

 “Ocrevus has the potential to really change the landscape and, from a patient perspective, sounds pretty easy.”
EU Key Opinion Leader

• The table of contents >
• The key questions answered >
• The key KOL quotes >
• See the 23 therapies covered >
• Find out who the 12 EU & US KOLs are >
• Review an extract from the report - 1 drug profile >

• Zinbryta (daclizumab; Biogen/AbbVie)
• Ocrevus (ocrelizumab; Roche/Biogen)
• ofatumumab (Novartis/Genmab)
• Biotin (MD 1003; MedDay/Medical Need)
• siponimod (BAF 312; Novartis)
• Plus 18 more – download the full list now >

• Prof Shiv Saidha, MD, MBBCh. Associate Professor of Neurology, Johns Hopkins Medicine, Baltimore, Maryland, USA.
• Prof Bianca Weinstock-Guttman, MD. Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo, New York, USA.
• Prof Mark Freedman, MD. Professor of Medicine in the field of Neurology, University of Ottawa and Director of the Multiple Sclerosis Research Unit, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.
• Prof Gilles Defer, MD. Head of the Department of Neurology, University Hospital of Caen, France.
• Prof Per Soelberg Sørensen, MD. Professor of Neurology, University of Copenhagen and Director of the Danish Multiple Sclerosis Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
• Plus 7 more – download the full list now >

• Once approved, Ocrevus will revolutionise MS treatment: Not just the relapsing remitting form but progressive forms as well, KOLs say. What are the most likely indications for Ocrevus, and will it see first-line usage?
• Interferons in decline: More neurologists are prescribing other agents instead, a trend KOLs expect to continue even as interferon use persists in specific indications. What’s behind the drop-off in interferon use, and in which patients will doctors continue to prescribe them?
• Next-generation sphingosine modulators may threaten Gilenya: What will these pipeline agents need to show to gain widespread adoption?
• Copaxone still going strong: Considered the safest MS therapy, Copaxone continues to appeal to risk-averse patients. Has the introduction of generic glatiramer acetate had an impact on Copaxone prescribing?
• Future unclear for Zinbryta: Launched into a crowded marked, Biogen/AbbVie’s Zinbryta may struggle to find a niche. What advantages and drawbacks do KOLs say will determine the drug’s short-term prospects? Which potential competitor looms longer-term?
• Tecfidera use has plateaued: Safety concerns have made neurologists more cautious about using Tecfidera. Do KOLs expect prescriptions to decline or stay the same? Which Tecfidera competitor is benefitting most from the uncertainty?
• KOLs excited about MD 1003: Intrigued by the potential of pharmaceutical-grade biotin, KOLs are calling for larger trials. What are their most pressing questions and concerns? Where do they see MD 1003 entering the treatment algorithm?
• Novel MoAs hold promise: Despite disappointing study results, KOLs are keeping a close eye on Biogen’s anti-LINGO-1 mAb, opicinumab. What has them interested, and what do they suggest as next steps for evaluating the drug?

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

• Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
• You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.